Abstract: Steering system for vehicles comprises a frame with a front axle and a rear axle, at least one of these carrying two steered wheels, the wheels of each axle being driven by a hydraulic motor via a differential unit, the steered wheels being connected, for steering control, to a cylinder-piston unit fed by a usual power steering device, in which at least the hydraulic motor associated with one axle is of variable piston displacement, and is associated with piston displacement adjustment means governed by the position of the cylinder of the cylinder-piston unit which controls the steering.

Abstract: Steering system for vehicles comprises a frame with a front axle and a rear axle, at least one of these carrying two steered wheels, the wheels of each axle being driven by a hydraulic motor via a differential unit, the steered wheels being connected, for steering control, to a cylinder-piston unit fed by a usual power steering device, in which at least the hydraulic motor associated with one axle is of variable piston displacement, and is associated with piston displacement adjustment means governed by the position of the cylinder of the cylinder-piston unit which controls the steering.

Abstract: A lawn mower includes a cutting unit having two rotors coupled together within a single casing which rotate in opposite directions. The rotors carry at least two aligned blades. The distance between the axes of the rotors is such that the areas covered by the blades when rotating are partially superposed in correspondence with an axis of symmetry of the pair of rotors which coincides with the mower axis. The direction of rotation of the two rotors is such that the direction of movement of the blades when in proximity to said axis of symmetry is the same as the forward travel direction of the mower.

Abstract: Oligosaccharides derived from natural or supersulphated GAGS or their mixtures, with a heparin content less than 1% by wt. having average molecular weight between 2,500 and 15,000 dalton, at least 50% by wt. of said oligosaccharide having a molecular weight in the +20% range in respect of the average molecular weight, providing an exceptional bioavailability and an antithrombin activity equal or higher than the starting GAGS.

Abstract: Iron complexes with conalbumin and its derivatives, such as acetylconalbumin and succinylconalbumin, with an iron content ranging from 2 to 30% by weight, useful for the treatment of sideropenic and hypochromic anaemia, preparation process and pharmaceutical compositions containing them as active ingredients.

Abstract: A process for preparing dermatan sulphate (DS) of pharmaceutical purity from animal organs rich in micropolysaccharides (MPS), by: a) stabilizing the fresh organs by freezing them either as such or in the form of powder, b) micronizing the material containing the MPS with an aqueous CaCl.sub.2 solution, c) digesting the homogenate comprising the raw material and the CaCl.sub.2 with proteolytic enzyme at alkaline pH and at low temperature, d) acidifying, heating and filtering the lysate, e) treating the filtrate with quaternary ammonium salts able to undergo complexing with and thus precipitate either the DS alone or all the MPS selectively, f) recovering and purifying the DS either directly from the ammonium salt complex containing it or from the complex obtained from the mixture of ammonium salt complexes of all the MPS by fractional solubilization with acetone.

Abstract: A process for the controlled preparation of low molecular weight glucosaminoglycans by treating conventional high molecular weight glucosaminoglycans in the solid state or in solution form with a rectilinear gamma ray beam at doses within the range of 2.5 to 20 Mrad supplied by successive irradiation stages with cooling intervals between one irradiation stage and the next in the dynamic phase.The mixture obtained is subjected to fractionation, purification, neutralization and lyophilization. The glucosaminoglycans obtained have a molecular weight of between 1000 and 35,000 daltons and are used for the preparation of pharmaceutical compositions possessing antithrombotic, fibinolytic, antiatherogenic and heparin cofactor II activation activity.

Abstract: A process for preparing dermatan sulphate (DS) of pharmaceutical purity from animal organs rich in mucopolysaccharides (MPS), by: (a) stabilizing the fresh organs by freezing them either as such or in the form of powder, (b) micronizing the material containing the MPS with an aqueous CaCl.sub.2 solution, (c) digesting the homogenate comprising the raw material and the CaCl.sub.2 with proteolytic enzymes at alkaline pH and at low temperature, (d) acidifying, heating and filtering the lysate, (e) treating the filtrate with quaternary ammonium salts able to undergo complexing with and thus precipitate either the DS along or all the MPS selectively, (f) recovering and purifying the DA either directly from the ammonium salt complex containing it or from the complex obtained from the mixture of ammonium salt complexes of all the MPS by fractional solubilization with acetone.

Abstract: A process for producing natural heparan sulphate and dermatan sulphate for mixtures of proteoglycans from the aorta, myocardium and particularly vascularized organs, based on a series of precipitation and purification steps which enable the protein part of the proteoglycan to be eliminated and the two products to be obtained in substantially pure form, without any chemical or enzymatic degradation.When administered orally or parenterally, the heparan sulphate obtained exerts activation effects on antithrombin III and on the fibrinolytic process.The dermatan sulphate obtained exerts an inhibiting effect on Factor Xa and also possesses the property of activating the fibrinolytic effect of heparan sulphate.